Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 142.70 -0.59 (0.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.29 | 52 Week High | $58.46 | |||
| Open | $142.74 | 52 Week Low | $31.25 | |||
| Day High | $143.83 | P/E | N/A | |||
| Day Low | $140.90 | EPS | $-0.69 | |||
| Volume | 1,033,367 | |||||
